Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | Immuno-oncology opportunities for the treatment of lymphoma

Anton Hagenbeek • 4 Dec 2015
ASH 2015
Hodgkin Lymphoma Non-Hodgkin Lymphoma Antibodies Brentuximab vedotin Checkpoint inhibitors

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Anton Hagenbeek, MD, PhD, from the University of Amsterdam, Amsterdam, Netherlands, discusses immuno-oncology mechanisms and pathways that can be targeted by immunotherapies for patients with Hodgkin lymphoma or non-Hodgkin lymphoma. Highlighted approaches that are being explored include immune checkpoint inhibitors and brentuximab vedotin, an anti-CD30 antibody-drug conjugate.

More from Anton Hagenbeek

12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights
23:19
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights
Anton Hagenbeek et al. • 9 Apr 2015
iwNHL 2015 roundtable: The changing treatment landscape for non-Hodgkin lymphoma
16:39
iwNHL 2015 roundtable: The changing treatment landscape for non-Hodgkin lymphoma
Andrew Zelenetz et al. • 3 Oct 2015
Brentuximib vedotin therapy for Hodgkin lymphoma
2:18
Brentuximib vedotin therapy for Hodgkin lymphoma
Anton Hagenbeek • 9 Dec 2014
What should the future of cancer treatment and research look like?
1:58
What should the future of cancer treatment and research look like?
Anton Hagenbeek • 9 Jun 2016

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals